<DOC>
	<DOCNO>NCT02291861</DOCNO>
	<brief_summary>The purpose study determine whether fixed-doses investigational drug , SD-809 ( deutetrabenazine ) , reduce severity abnormal involuntary movement tardive dyskinesia .</brief_summary>
	<brief_title>Addressing Involuntary Movements Tardive Dyskinesia</brief_title>
	<detailed_description />
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<criteria>History use dopamine receptor antagonist least 3 month Clinical diagnosis tardive dyskinesia symptom least 3 month prior screen Subjects underlie psychiatric diagnosis stable change psychoactive medication Have mental health provider anticipate change treatment regimen next 3 month History compliant prescribe medication Able swallow study drug whole Be good general health expect attend study visit complete study assessment Female subject must pregnant must agree acceptable method contraception throughout study Currently receive medication treatment tardive dyskinesia Have neurological condition tardive dyskinesia may interfere assess severity dyskinesia Have serious untreated undertreated psychiatric illness Have recent history presence violent behavior Have unstable serious medical illness Have evidence hepatic impairment Have evidence renal impairment Have know allergy component SD809 tetrabenazine Has participate investigational drug device trial receive study drug device within 30 day Have acknowledge use illicit drug Have history alcohol substance abuse previous 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Dyskinesias</keyword>
	<keyword>Movement Disorders</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Neurologic Manifestations</keyword>
	<keyword>Signs Symptoms</keyword>
</DOC>